Page last updated: 2024-11-04

moxonidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Moxonidine is an antihypertensive drug that acts as an imidazoline I1-receptor agonist. Its synthesis involves a multi-step process starting with the condensation of 2-chloro-6-fluorobenzaldehyde with 2-amino-4,5-dihydroimidazole. It primarily acts by stimulating I1-receptors in the brainstem, leading to decreased sympathetic nerve activity and a reduction in blood pressure. Moxonidine has been shown to be effective in treating hypertension, particularly in patients with resistant hypertension. The drug is studied for its potential to improve cardiovascular health and reduce the risk of cardiovascular events. The importance of moxonidine research stems from its unique mechanism of action, its efficacy in treating hypertension, and its potential to provide a novel treatment option for patients with cardiovascular disease.'

moxonidine: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID4810
CHEMBL ID19236
CHEBI ID7009
SCHEMBL ID49143
MeSH IDM0127943

Synonyms (119)

Synonym
4-chloro-5-(2-imidazolin-2-ylamino)-6-methoxy-2-methylpyrimidine
moxonidinum [latin]
moxonidina [spanish]
4-chloro-5-(2-imidazolidinyldeneamino)-6-methoxy-2-methylpyrimidine
bdbm50050093
(4-chloro-6-methoxy-2-methyl-pyrimidin-5-yl)-imidazolidin-2-ylidene-amine
2-(4-chloro-6-methoxy-2-methyl-pyrimidin-5-ylamino)-4,5-dihydro-3h-imidazol-1-ium
BRD-K77771411-001-04-4
be-5895
moxonidine hydrochloride hydrate
ly-326869
lopac-m-1559
NCGC00015649-02
NCGC00015649-01
cas-75438-57-2
PDSP1_000177
PRESTWICK3_001016
cynt (tn)
D05087
moxonidine (usan/inn)
LOPAC0_000753
PDSP2_000176
PRESTWICK2_001016
BSPBIO_001171
bdf 5895
nucynt
cynt
lomox
ly 326869
5-pyrimidinamine, 4-chloro-n-(4,5-dihydro-1h-imidazol-2-yl)-6-methoxy-2-methyl- (9ci)
5-pyrimidinamine, 4-chloro-n-(4,5-dihydro-1h-imidazol-2-yl)-6-methoxy-2-methyl-
4-chloro-6-methoxy-2-methyl-5-(2-imidazolin-2-yl)aminopyrimidine
2-(6-chloro-4-methoxy-2-methylpyrimidin-5-ylamino)-2-imidazoline
norcynt
normoxocin
4-chloro-n-(4,5-dihydro-1h-imidazol-2-yl)-6-methoxy-2-methyl-5-pyrimidinamine
be 5895
AB00514003
C07451
moxonidine
75438-57-2
PRESTWICK0_001016
SPBIO_003042
PRESTWICK1_001016
BPBIO1_001289
NCGC00092355-02
AC-637
NCGC00015649-05
MLS002222183
smr000857402
chebi:7009 ,
ly326869
be5895
CHEMBL19236 ,
bdf-5896
bdf5896
FT-0657360
HMS1571K13
4-chloro-n-(4,5-dihydro-1h-imidazol-2-yl)-6-methoxy-2-methylpyrimidin-5-amine
4-chloro-n-(4,5-dihydro-1h-imidazol-2-yl)-6-methoxy-2-methyl-pyrimidin-5-amine hydrochloride;moxonidine
A838414
HMS2098K13
unii-cc6x0l40gw
moxonidinum
cc6x0l40gw ,
moxonidina
moxonidine [usan:inn:ban]
monoxidine [common misspelling of moxonidine]
dtxcid3025170
tox21_110190
dtxsid5045170 ,
CCG-204838
HMS2230B15
AKOS015997932
NCGC00015649-04
FT-0601601
S2066
AKOS015895873
HMS3373O04
moxonidine [inn]
moxonidine [mart.]
moxonidine [ep monograph]
moxonidine [mi]
moxonidine [who-dd]
moxonidine [usan]
HY-B0374
4-chloro-n-imidazolidin-2-ylidene-6-methoxy-2-methylpyrimidin-5-amine
SCHEMBL49143
AB00514003-08
tox21_110190_1
NCGC00015649-08
AF-0062
4-chloro-n-(imidazolin-2-ylidene)-6-methoxy-2-methyl-5-pyrimidinamine
4-chloro-n-(imidazolidin-2-ylidene)-6-methoxy-2-methylpyrimidin-5-amine
STL419983
M2660
AB00514003_10
DB09242
(2r,4r)-1-[(2s)-5-[(aminoiminomethyl)amino]-1-oxo-2-[[(1,2,3,4-tetrahydro-3-methyl-8- quinolinyl)sulfonyl]amino]pentyl]-4-methyl-2-piperidinecarboxylic acid
STL450991
bdf5895
mfcd22689455
HMS3655B17
moxonidine; 4-chloro-n-(imidazolidin-2-ylidene)-6-methoxy-2-methylpyrimidin-5-amine
moxonidine 1.0 mg/ml in methanol
SR-01000075981-7
HMS3715K13
SW196502-4
BCP23003
bdf5895;bdf-5895;bdf 5895;be 5895; be-5895; be5895
Q419944
75438-57-2 (free base)
1008754-16-2
EX-A3409
SDCCGSBI-0050731.P002
NCGC00015649-17
HMS3747A03
EN300-7360649
gtpl12574

Research Excerpts

Overview

Moxonidine is an oral antihypertensive drug from the group of 2nd generation sympatholytics. It is a selective I1-imidazoline receptor agonist, similar to clonidine but with no α2-adrenergic agonist activity and subsequently fewer side effects.

ExcerptReferenceRelevance
"Moxonidine is an oral antihypertensive drug from the group of 2nd generation sympatholytics. "( The use of moxonidine in the treatment of arterial hypertension.
Vachek, J, 2021
)
2.45
"Moxonidine is a centrally acting antihypertensive agent with a selectivity to I"( Peripheral versus central effect of intravenous moxonidine on rat carotid sinus baroreflex-mediated sympathetic arterial pressure regulation.
Kawada, T; Miyamoto, T; Shimizu, S; Shishido, T; Sugimachi, M; Yamamoto, H, 2017
)
2.15
"Moxonidine is a selective I1-imidazoline receptor agonist, similar to clonidine but with no α2-adrenergic agonist activity and subsequently fewer side effects."( Moxonidine for tramadol withdrawal symptoms during detoxification.
Ghossoub, E; Talih, F, 2015
)
2.58
"Moxonidine is a selective imidazoline receptor agonist with comparable blood pressure-lowering efficacy to first-line antihypertensives and favorable metabolic effects. "( Effect of moxonidine and amlodipine on serum YKL-40, plasma lipids and insulin sensitivity in insulin-resistant hypertensive patients-a randomized, crossover trial.
Majer, J; Masajtis-Zagajewska, A; Nowicki, M, 2010
)
2.21
"Moxonidine is a centrally-active imidazoline compound with preferential affinity for imidazoline receptors (IR) over alpha(2)-adrenoceptors (alpha(2)AR). "( Non-adrenergic exploratory behavior induced by moxonidine at mildly hypotensive doses.
Paul, IA; Peeler, DF; Piletz, JE; Stec, DE; Zhu, H, 2003
)
2.02
"Moxonidine is a mixed alpha(2)-adrenergic and imidazoline receptor agonist with an improved side effect profile compared to clonidine. "( Moxonidine, a mixed alpha(2)-adrenergic and imidazoline receptor agonist, identifies a novel adrenergic target for spinal analgesia.
Fairbanks, CA; Stone, LS; Wilcox, GL, 2003
)
3.2
"Moxonidine is an I1-imidazoline receptor agonist that reduces blood pressure by inhibition of central sympathetic activity. "( The I1-imidazoline agonist moxonidine decreases sympathetic tone under physical and mental stress.
Bührmann, S; Mitchell, A; Philipp, T; Schäfers, RF; Siffert, W; Wenzel, RR, 2004
)
2.06
"Moxonidine is a centrally active imidazoline receptor agonist that effectively lowers blood pressure and has been shown to have beneficial effects on lipid and carbohydrate metabolism. "( Moxonidine in the treatment of overweight and obese patients with the metabolic syndrome: a postmarketing surveillance study.
Marsalek, P; Sharma, AM; Wagner, T, 2004
)
3.21
"Moxonidine is a sympathoinhibitory and antihypertensive agent that is thought to be a ligand of alpha(2)-adrenergic receptors and imidazoline type-1 receptors in the RVLM."( Effect of moxonidine on putative sympathetic neurons in the rostral ventrolateral medulla of the rat.
Granata, AR,
)
1.26
"Moxonidine is a second-generation centrally acting antihypertensive drug that has a high affinity for I(1)-imidazoline receptors (I(1)R). "( Sympathoexcitation of moxonidine in the caudal ventrolateral medulla is dependent on I1-imidazoline receptors in anesthetized rats.
Gao, L; Wang, LG; Wang, W; Wang, WZ; Yuan, WJ, 2007
)
2.1
"Moxonidine is an antihypertensive imidazoline compound that reduces blood pressure primarily by central inhibition of sympathetic outflow and by direct actions on the heart to release atrial natriuretic peptide, a vasodilator and an antihypertrophic cardiac hormone."( Control of left ventricular mass by moxonidine involves reduced DNA synthesis and enhanced DNA fragmentation.
Danalache, B; DeBlois, D; Duguay, D; El-Ayoubi, R; Gutkowska, J; Menaouar, A; Mukaddam-Daher, S; Paquette, PA, 2008
)
1.34
"Moxonidine is a centrally acting antihypertensive with a selective action on I1-imidazoline receptors in RVLM."( Selective antihypertensive action of moxonidine is mediated mainly by I1-imidazoline receptors in the rostral ventrolateral medulla.
Dreshaj, I; Ernsberger, P; Haxhiu, MA; Schäfer, SG, 1994
)
1.28
"Moxonidine is a centrally acting antihypertensive agent with potent action on I1-imidazoline receptors. "( Antiarrhythmic effect of the selective I1-imidazoline receptor modulator moxonidine on ouabain-induced cardiac arrhythmia in guinea pigs.
Mest, HJ; Raap, A; Thomsen, P, 1995
)
1.97
"Moxonidine is an imidazoline receptor modulator, specific for the I1-imidazoline receptor. "( Clinical experience with moxonidine.
Prichard, BN, 1994
)
2.03
"Moxonidine is a second-generation, centrally acting antihypertensive drug with a distinctive mode of action. "( Pharmacology of moxonidine, an I1-imidazoline receptor agonist.
Ernsberger, P; Haxhiu, MA; Kaan, EC; Papp, JG; Ziegler, D, 1996
)
2.08
"Moxonidine is an imidazoline I1-receptor modulator."( Effective antihypertensive therapy: blood pressure control with moxonidine.
Graham, BR; Prichard, BN, 1996
)
1.25
"Moxonidine is an effective and well-tolerated antihypertensive, at least as good as other established forms of antihypertensive medication. "( Placebo-controlled comparison of the efficacy and tolerability of once-daily moxonidine and enalapril in mild-to-moderate essential hypertension.
Gräve, MA; Hughes, PR; Jäger, BA; Kaan, EC; Küppers, HE; Luszick, JH, 1997
)
1.97
"Moxonidine is a centrally acting antihypertensive. "( Pharmacology and clinical use of moxonidine, a new centrally acting sympatholytic antihypertensive agent.
Graham, BR; Owens, CW; Prichard, BN, 1997
)
2.02
"Moxonidine is an imidazoline compound which acts on I1 imidazoline 'receptors' in the central nervous system to reduce blood pressure. "( Moxonidine: a review.
Morris, ST; Reid, JL, 1997
)
3.18
"Moxonidine is an imidazoline I1-receptor agonist that centrally acts by reducing the sympathetic tone. "( Effects of moxonidine on stress-induced peak blood pressure and renal function: a randomized, double-blind, placebo-controlled crossover study.
Fauvel, JP; Laville, M; Maakel, N; Najem, R; Pozet, N, 1998
)
2.13
"Moxonidine is a new centrally acting agent showing selective agonism of imidazoline I1 receptors, but very little alpha2-adrenoceptor agonism."( Safety and tolerability of moxonidine in the treatment of hypertension.
Jäger, B; Luszick, J; Schachter, M; Söhlke, E; Verboom, C, 1998
)
1.32
"Moxonidine is an I1-imidazoline receptor agonist that reduces blood pressure in hypertensives. "( I1-imidazoline agonist moxonidine decreases sympathetic nerve activity and blood pressure in hypertensives.
Lüscher, TF; Noll, G; Qui, S; Shaw, S; Spieker, L; Wenzel, RR, 1998
)
2.05
"Moxonidine is a centrally acting antihypertensive. "( Moxonidine: a new antiadrenergic antihypertensive agent.
Graham, BR; Owens, CW; Prichard, BN, 1999
)
3.19
"Moxonidine is a new antihypertensive agent whose mechanism of action appears to involve specific stimulation of imidazoline receptors resulting in an inhibition of the activity of the central and peripheral sympathetic nervous system. "( The effect of moxonidine on plasma lipid profile and on LDL subclass distribution.
Bairaktari, E; Elisaf, MS; Karabina, SA; Petris, C; Siamopoulos, KC; Tselepis, A; Tzallas, C, 1999
)
2.11
"Moxonidine is an antihypertensive drug that lowers sympathetic vasomotor tone by stimulating either alpha2-adrenergic (alpha2-AR) or imidazoline I1 receptors within the rostral ventrolateral medulla (RVL). "( Prototypical imidazoline-1 receptor ligand moxonidine activates alpha2-adrenoceptors in bulbospinal neurons of the RVL.
Guyenet, PG; Hayar, A, 2000
)
2.01
"Moxonidine is an imidazoline ligand acting on the central nervous system (CNS) receptors to decrease sympathetic activation."( The effects of moxonidine, a novel imidazoline, on plasma norepinephrine in patients with congestive heart failure. Moxonidine Investigators.
Bergh, CH; Dickstein, K; McNay, J; Steinberg, M; Swedberg, K, 2000
)
1.38
"Moxonidine is a mixed I(1) imidazoline/alpha(2)moxonidine=morphine. "( Effects of the I(1) imidazoline/alpha(2)-adrenergic receptor agonist moxonidine in comparison with clonidine in the formalin test in rats.
Lutz, EA; Shannon, HE, 2000
)
1.98
"Moxonidine is a centrally acting anti-hypertensive drug with potent action on I1-imidazoline receptors."( Effects of moxonidine on corticocerebral blood flow under normal and ischemic conditions in conscious rabbits.
Csete, K; Papp, JG, 2000
)
1.42
"Moxonidine is an imidazoline receptor agonist that is highly selective for the I1-imidazoline receptor with little effect at the central alpha2-receptor."( Moxonidine: a new and versatile antihypertensive.
Messerli, F, 2000
)
2.47
"Moxonidine is a centrally acting antihypertensive agent which has been found to exert its blood pressure lowering effect by interaction with (alpha2-adrenoceptors and imidazoline receptors of the I(1)-type. "( Site of action of moxonidine in the rat nephron.
Greven, J; von Bronewski-Schwarzer, B, 2001
)
2.09
"Moxonidine is a new centrally active imidazoline-receptor agonist being effectively applied in the treatment of arterial hypertension due to its sympathicolytic potency. "( [Effect of the imidazoline receptor agonist moxonidine on hemodynamics, coronary circulation, metabolic ischemia markers and the neurohumoral system in patients with essential hypertension. Effects of moxonidine on coronary circulation].
Hamel, M; Hamm, C; Miric, M; Mitrovic, V; Thormann, J, 2001
)
2.01
"Moxonidine is a centrally acting anti-sympathetic drug, which suppresses sympathetic nervous system outflow by stimulation of central imidazoline receptors located in the rostral ventro-lateral medulla."( Effects of central sympathetic inhibition on heart rate variability during steady-state exercise in healthy humans.
De Vito, G; Galloway, SD; Maas, P; McMurray, JJ; Nimmo, MA, 2002
)
1.04
"Moxonidine is a new centrally acting anti-hypertensive with a very low adverse drug reaction profile. "( Influence of food on the oral bioavailability of moxonidine.
Michaelis, K; Müller, M; Theodor, RA; Weber, W; Weimann, HJ,
)
1.83
"Moxonidine is a new centrally acting alpha 2-adrenoceptor agonist that differs from others by a lower incidence of side effects in hypertensive patients. "( Pharmacodynamic action and pharmacokinetics of moxonidine after single oral administration in hypertension patients.
Hutt, HJ; Kirch, W; Plänitz, V, 1990
)
1.98

Effects

Moxonidine has been found to have an approximately 600 fold greater affinity for I1 imidazoline preferring sites as compared to alpha 2-adrenoceptors in the rat kidney. The drug has been compared with representatives from each important class of antihypertensive drugs, with diuretics, clonidine and calcium antagonists.

ExcerptReferenceRelevance
"Moxonidine has a favourable side-effect profile, at least in part due to its lack of effect on central alpha2 receptors."( Moxonidine: a new antiadrenergic antihypertensive agent.
Graham, BR; Owens, CW; Prichard, BN, 1999
)
2.47
"Moxonidine has unique effects on a number of cell types through this unusual cellular site of action."( Pharmacological properties of the central antihypertensive agent, moxonidine.
Brown-Bryan, TA; Edwards, LP; Ernsberger, P; McLean, L, 2012
)
1.34
"Moxonidine has been compared with representatives from each important class of antihypertensive drugs."( Clinical experience with moxonidine.
Prichard, BN, 1994
)
1.31
"1. Moxonidine has been found to have an approximately 600 fold greater affinity for I1 imidazoline preferring sites as compared to alpha 2-adrenoceptors in the rat kidney. "( Renal imidazoline preferring sites and solute excretion in the rat.
Allan, DR; Penner, SB; Smyth, DD, 1993
)
0.91
"Moxonidine has been compared with representatives from each important class of antihypertensive drugs, with diuretics, clonidine, calcium antagonists, angiotensin-converting enzyme inhibitors, and both alpha- and beta- blocking drugs."( Effective antihypertensive therapy: blood pressure control with moxonidine.
Graham, BR; Prichard, BN, 1996
)
1.25
"Moxonidine has been compared with representatives from each important class of antihypertensive drugs, with clonidine, diuretics, both alpha- and beta-blocking drugs, calcium antagonists and angiotensin converting enzyme inhibitors."( The use of moxonidine in the treatment of hypertension.
Graham, BR; Prichard, BN, 1997
)
1.41
"Moxonidine has been shown to be antiarrhythmic during ischaemia in vivo. "( Facilitation of spontaneous defibrillation by moxonidine during regional ischaemia in an isolated working rabbit heart model.
Cobbe, SM; Hicks, MN; Kane, KA; Wolk, R, 1999
)
2
"Moxonidine has been shown to improve glucose tolerance in man, probably by two different mechanisms, i.e."( Therapy of hypertension and metabolic syndrome: today's standard and tomorrow's perspectives.
Hansson, L, 1998
)
1.02
"Moxonidine has been shown to be suitable for administration once daily."( Moxonidine: a new antiadrenergic antihypertensive agent.
Graham, BR; Owens, CW; Prichard, BN, 1999
)
2.47
"Moxonidine also has beneficial effects in animal models of diabetes and kidney disease."( Moxonidine: some controversy.
Doggrell, SA, 2001
)
2.47
"Moxonidine has been shown to diminish sympathetic activity, as measured by norepinephrine, epinephrine and plasma renin activity."( Moxonidine: a new and versatile antihypertensive.
Messerli, F, 2000
)
2.47
"Moxonidine has favorable effects on hemodynamics and the neurohumoral system in patients with essential hypertension and is well tolerated at the dose administered."( Hemodynamic and neurohumoral effects of moxonidine in patients with essential hypertension.
Hüting, J; Mitrovic, V; Patyna, W; Schlepper, M, 1991
)
1.27

Actions

Moxonidine did not suppress the elevation in the startle response caused by d-amphetamine. The increase in uveoscleral outflow is mediated by alpha2 adrenergic receptors, not by I1 imidazoline receptors.

ExcerptReferenceRelevance
"The moxonidine-induced increase of uveoscleral outflow is mediated by alpha2 adrenergic receptors, not by I1 imidazoline receptors."( Effect of moxonidine on the uveoscleral outflow: role of alpha2-adrenoceptors or i1 imidazoline receptors.
Sun, N; Xiong, Q; Yang, J; Yang, R, 2009
)
1.24
"moxonidine produced an increase in sodium excretion and urine flow fate."( Central and renal I1 imidazoline preferring receptors: two unique sites mediating natriuresis in the rat.
Penner, SB; Smyth, DD, 1994
)
1.01
"Moxonidine did not suppress the elevation in the startle response caused by d-amphetamine."( Moxonidine, a selective imidazoline-1 receptor agonist, suppresses the effects of ethanol withdrawal on the acoustic startle response in rats.
Kallman, MJ; Rasmussen, K; Vandergriff, J, 2000
)
2.47
"Moxonidine delayed this increase by 9.8 weeks."( Pharmacodynamic models for the cardiovascular effects of moxonidine in patients with congestive heart failure.
Brynne, L; Karlsson, MO; McNay, JL; Schaefer, HG; Swedberg, K; Wiltse, CG, 2001
)
1.28

Treatment

Pretreatment with moxonidine (0.01, 0.1, and 1.0 mg/kg, subcutaneously) significantly attenuated the ethanol withdrawal-induced elevation of the acoustic startle response. The treatment was associated with lower recurrence risk after adjustment for age, body mass index, number of AF episodes in the previous year, and left atrial diameter.

ExcerptReferenceRelevance
"Moxonidine treatment was associated with lower recurrence risk after adjustment for age, body mass index, number of AF episodes in the previous year, and left atrial diameter (adjusted hazard ratio, 0.35 [95% CI, 0.22-0.55]; P<0.001)."( Central sympathetic inhibition to reduce postablation atrial fibrillation recurrences in hypertensive patients: a randomized, controlled study.
Deftereos, S; Doudoumis, K; Efremidis, M; Giannopoulos, G; Katsivas, A; Kossyvakis, C; Letsas, K; Manolis, AS; Panagopoulou, V; Pyrgakis, V; Raisakis, K; Rentoukas, I; Stefanadis, C; Tousoulis, D, 2014
)
1.12
"Moxonidine treatment as a centrally acting antihypertensive agent was found to be very beneficial in the treatment of vasospasm by increasing the angiographic diameter and the pathologic luminal area and reducing muscular wall thickness."( Beneficial effects of moxonidine on cerebral vasospasm after experimental subarachnoid hemorrhage.
Esen, H; Ilik, MK; Koc, O; Kocaogullar, Y, 2014
)
2.16
"Moxonidine pretreatment significantly blunted cardiovascular sensitivity to injection of tempol (5 nmol) or angiotensin II (10 pmol) into the RVLM in SHR."( Centrally acting drug moxonidine decreases reactive oxygen species via inactivation of the phosphoinositide-3 kinase signaling in the rostral ventrolateral medulla in hypertensive rats.
Hu, QK; Tan, X; Wang, WZ; Wang, YK; Wu, ZT; Yang, YH; Yu, Q; Yuan, WJ; Zhang, RW, 2016
)
1.47
"Moxonidine treatment did not alter daily urinary sodium and potassium excretions, but 120 microg/kg/h moxonidine decreased urine volume after 2 days and increased cyclic guanosine 3'5'monophosphate excretion on days 4 to 7 of treatment."( Chronic imidazoline receptor activation in spontaneously hypertensive rats.
El-Ayoubi, R; Gutkowska, J; Jankowski, M; Menaouar, A; Mukaddam-Daher, S, 2002
)
1.04
"moxonidine. The treatments produced no change in heart rate (HR) and hindlimb vascular resistance."( Central moxonidine on salivary gland blood flow and cardiovascular responses to pilocarpine.
Colombari, E; De Luca, LA; Menani, JV; Moreira, TS; Renzi, A; Takakura, AC, 2003
)
1.47
"Moxonidine treatment may improve unfavourable metabolic status related to insulin resistance by increasing adiponectin levels in patients with essential hypertension."( Effects of sympatholytic therapy with moxonidine on serum adiponectin levels in hypertensive women.
Caglayan, O; Ebinç, FA; Ebinç, H; Ozkurt, ZN; Ucardag, D; Yilmaz, M,
)
1.12
"Moxonidine pretreatment (0.03 and 0.10 mg/kg) decreased the incidence of ventricular fibrillation (25 and 30% versus 64%) and increased the number of animals that survived without developing any arrhythmia (20 and 25% versus 0%)."( Effect of moxonidine on arrhythmias induced by coronary artery occlusion and reperfusion.
Leprán, I; Papp, JG, 1994
)
1.41
"The moxonidine-treated (6 and 10 mg/kg) obese animals had significantly lower fasting plasma levels of insulin (17% and 19%, respectively) and free fatty acids (36% and 28%, respectively), whereas plasma glucose was not altered."( Antihypertensive agent moxonidine enhances muscle glucose transport in insulin-resistant rats.
Fogt, DL; Gödicke, J; Henriksen, EJ; Jacob, S; Youngblood, EB, 1997
)
1.09
"Moxonidine treatment reduced fasting insulin levels by 71% in SHROB and lowered plasma free fatty acids by 25%."( Mechanisms of antihyperglycemic effects of moxonidine in the obese spontaneously hypertensive Koletsky rat (SHROB).
Bedol, D; Ernsberger, P; Farrell, CJ; Friedman, JE; Ishizuka, T; Koletsky, RJ; Liu, S, 1999
)
1.29
"Moxonidine treatment enhanced the expression of IRS-1 protein in skeletal muscle by 74% in SHROB and 40% in SHR."( Anti-hyperglycemic activity of moxonidine: metabolic and molecular effects in obese spontaneously hypertensive rats.
Bedol, D; Ernsberger, P; Farrell, CJ; Friedman, JE; Ishizuka, T; Koletsky, RJ; Liu, S, 1998
)
1.31
"Moxonidine treatment improved insulin sensitivity in insulin-resistant, obese patients with mild hypertension, but not in insulin-sensitive obese subjects with mild hypertension, when compared to placebo. "( Moxonidine improves insulin sensitivity in insulin-resistant hypertensives.
Haenni, A; Lithell, H, 1999
)
3.19
"Moxonidine treatment significantly reduced plasma noradrenaline concentration (P < 0.01), mean arterial pressure (P < 0.01), and blood glycerol concentration (P < 0.05), but no differences were observed in heart rate, the ventilatory response to exercise or subjective ratings of dyspnoea and exertion."( Effects of sympathetic inhibition on exertional dyspnoea, ventilatory and metabolic responses to exercise in normotensive humans.
De Vito, G; Galloway, SD; McClure, S; McMurray, JJ; Nimmo, MA, 2000
)
1.03
"Treatment with moxonidine, NDDCT and TBZ significantly attenuated 3-NPA induced reduction in body weight, locomotor activity, grip strength, anxiety as well as impaired learning and memory."( Pharmacological benefit of I(1)-imidazoline receptors activation and nuclear factor kappa-B (NF-κB) modulation in experimental Huntington's disease.
Gupta, S; Sharma, B, 2014
)
0.74
"Treatment with moxonidine is associated with less AF recurrences after ablation treatment for drug-refractory AF in patients with hypertension. "( Central sympathetic inhibition to reduce postablation atrial fibrillation recurrences in hypertensive patients: a randomized, controlled study.
Deftereos, S; Doudoumis, K; Efremidis, M; Giannopoulos, G; Katsivas, A; Kossyvakis, C; Letsas, K; Manolis, AS; Panagopoulou, V; Pyrgakis, V; Raisakis, K; Rentoukas, I; Stefanadis, C; Tousoulis, D, 2014
)
0.76
"Pretreatment with moxonidine abolished the hypotensive but not the tachycardic effect of ethanol."( Adenosinergic modulation of the imidazoline I₁-receptor-dependent hypotensive effect of ethanol in acute renal failure.
El-Gowelli, HM; El-Mas, MM; Ghazal, AR; Harraz, OF; Mohy El-Din, MM, 2012
)
0.7
"Treatment with moxonidine in six patients who completed the study resulted in a 10/5 mmHg reduction in 24-h ambulatory blood pressure (p = 0.01)."( Effect of moxonidine on lipid subfractions in patients with hypertension.
Chik, G; Lumb, PJ; McMahon, Z; Wierzbicki, AS, 2004
)
1.07
"Pretreatment with moxonidine (0.01, 0.1, and 1.0 mg/kg, subcutaneously), but not clonidine (0.3, 1.0, and 3.0 mg/kg, subcutaneously), significantly attenuated the ethanol withdrawal-induced elevation of the acoustic startle response."( Moxonidine, a selective imidazoline-1 receptor agonist, suppresses the effects of ethanol withdrawal on the acoustic startle response in rats.
Kallman, MJ; Rasmussen, K; Vandergriff, J, 2000
)
2.07
"The treatment with moxonidine (5, 10 and 20 nmol in 1 microl) injected i.c.v."( Moxonidine reduces pilocarpine-induced salivation in rats.
De Luca, LA; Menani, JV; Moreira, TS; Renzi, A; Thomaz, AC, 2001
)
2.07

Toxicity

ExcerptReferenceRelevance
"Classical centrally acting antihypertensive agents lower blood pressure by reducing excessive sympathetic tone; however, their clinical use is limited by an adverse effect profile resulting from alpha2-adrenoceptor agonism."( Safety and tolerability of moxonidine in the treatment of hypertension.
Jäger, B; Luszick, J; Schachter, M; Söhlke, E; Verboom, C, 1998
)
0.6
" The most prominent adverse effects have been dry mouth, sedation, dizziness and oedema."( Moxonidine: a review of safety and tolerability after seven years of clinical experience.
Schachter, M, 1999
)
1.75
" The significant side effect was observed only in one patient."( Safety and efficacy of moxonidine in mild to moderate hypertension.
Jain, S; Kumari, S; Malhotra, P; Varma, S, 2001
)
0.62
"Moxonidine thus appears to be safe and effective antihypertensive drug in patients with essential hypertension."( Safety and efficacy of moxonidine in mild to moderate hypertension.
Jain, S; Kumari, S; Malhotra, P; Varma, S, 2001
)
2.06
" No adverse effects were reported during the study."( [The efficacy and safety of moxonidine in patients with metabolic syndrome (the O.B.E.Z.I.T.A. trial)].
Chroust, K; Krupicka, J; Soucek, M, 2011
)
0.66

Pharmacokinetics

The aim of the study presented here was to determine possible pharmacokinetic interactions of moxonidine and glibenclamide at steady state in 18 healthy male volunteers.

ExcerptReferenceRelevance
"The potential for pharmacokinetic interactions between moxonidine and digoxin at steady-state was investigated in 15 healthy male volunteers."( Lack of pharmacokinetic interactions between moxonidine and digoxin.
Pabst, G; Weber, W; Weimann, HJ, 1992
)
0.79
"3mg once daily for 7 days and both pharmacokinetic and pharmacodynamic data were determined."( The influence of renal function on clinical pharmacokinetics of moxonidine.
Hutt, HJ; Kirch, W; Plänitz, V, 1988
)
0.51
"The aim of the study presented here was to determine possible pharmacokinetic interactions of moxonidine and glibenclamide at steady state in 18 healthy male volunteers."( Steady state investigation of possible pharmacokinetic interactions of moxonidine and glibenclamide.
Achtert, G; Dilger, C; Eden, G; Michaelis, K; Müller, M; Weber, W; Weimann, HJ,
)
0.58
" These drugs must be administered parenterally and have a half-life of only a few minutes."( Clinical pharmacokinetics of vasodilators. Part II.
Heintz, B; Kirsten, D; Kirsten, R; Nelson, K, 1998
)
0.3
"Deriving a population pharmacokinetic model from real data is always associated with numerous assumptions."( Assumption testing in population pharmacokinetic models: illustrated with an analysis of moxonidine data from congestive heart failure patients.
Jonsson, EN; Karlsson, MO; Wade, JR; Wiltse, CG, 1998
)
0.52
"Although similar typical population estimates for the drug action-related parameters were obtained with use of manual blood pressure data and 24-hour ambulatory blood pressure measurements, the latter allowed for a more detailed description of the individual pharmacodynamic profiles because interindividual variability in pharmacodynamic parameters could be estimated together with increased precision in parameter estimates."( Comparison of manual versus ambulatory blood pressure measurements with pharmacokinetic-pharmacodynamic modeling of antihypertensive compounds: application to moxonidine.
Callies, S; de Alwis, DP; Mitchell, M; Schaefer, HG; Tillmann, C; Trocóniz, IF, 2000
)
0.5
" Pharmacokinetic parameters were calculated using a noncompartmental analysis method."( Quinidine does not affect the renal clearance of moxonidine.
Chan, C; He, MM; Mitchell, MI; Pouliquen, IJ; Schaefer, HG; Wise, SD, 2002
)
0.57
"To compare the performance of the standard lag time model (LAG model) with the performance of an analytical solution of the transit compartment model (TRANSIT model) in the evaluation of four pharmacokinetic studies with four different compounds."( Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies.
Jonker, DM; Karlsson, MO; Kerbusch, T; Savic, RM, 2007
)
0.34
"The population pharmacokinetic analyses were performed using NONMEM on concentration-time data of glibenclamide, furosemide, amiloride, and moxonidine."( Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies.
Jonker, DM; Karlsson, MO; Kerbusch, T; Savic, RM, 2007
)
0.54
" The parameter estimates related to the absorption differed between the two models while the estimates of the pharmacokinetic disposition parameters were similar."( Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies.
Jonker, DM; Karlsson, MO; Kerbusch, T; Savic, RM, 2007
)
0.34
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35

Compound-Compound Interactions

ExcerptReferenceRelevance
" One group received moxonidine, 40 mg, alone in the morning, the other had moxonidine in the same dose in combination with melatonin, 3 mg, overnight."( [Effect of moxonidine monotherapy and in combination with melatonin on hemodynamic parameters in patients with arterial hypertension].
Akhmetov, KZh; Komarov, FI; Shakirova, AN; Teĭblium, MM; Zaslavskaia, RM, 2000
)
1.02

Bioavailability

Moxonidine is well tolerated; its bioavailability after oral intake reaches 90%. The relative bioavailability of mox onidine administered under non-fasting conditions reached 94% of the bioavailability.

ExcerptReferenceRelevance
" The relative bioavailability of moxonidine administered under non-fasting conditions reached 94% of the bioavailability after fasted administration."( Influence of food on the oral bioavailability of moxonidine.
Michaelis, K; Müller, M; Theodor, RA; Weber, W; Weimann, HJ,
)
0.67
" intravenous solution, treatment B) were tested to investigate absolute bioavailability and pharmacokinetics of moxonidine."( Absolute bioavailability of moxonidine.
Michaelis, K; Theodor, R; Weber, W; Weimann, HJ,
)
0.64
" In the presence of moxonidine, a minor decrease of bioavailability of glibenclamide was detectable, as could be derived from the AUC and clearance data."( Steady state investigation of possible pharmacokinetic interactions of moxonidine and glibenclamide.
Achtert, G; Dilger, C; Eden, G; Michaelis, K; Müller, M; Weber, W; Weimann, HJ,
)
0.69
" After oral administration Tmax is about 1 h and bioavailability approaches 90%."( Effective antihypertensive therapy: blood pressure control with moxonidine.
Graham, BR; Prichard, BN, 1996
)
0.53
"Following oral administration, maximum concentration is reached at about 1 h, and bioavailability approaches 90%."( The use of moxonidine in the treatment of hypertension.
Graham, BR; Prichard, BN, 1997
)
0.69
" After oral administration Tmax is about 1 h, bioavailability approaches 90%."( Pharmacology and clinical use of moxonidine, a new centrally acting sympatholytic antihypertensive agent.
Graham, BR; Owens, CW; Prichard, BN, 1997
)
0.58
" In summary, moxonidine is well absorbed after oral administration."( Metabolism and disposition of the antihypertensive agent moxonidine in humans.
Abraham, TL; Czeskis, B; He, MM; Lindsay, TJ; Mitchell, MI; Oliver, SD; Payne, C; Pouliquen, IJ; Schaefer, HC; Shipley, LA, 2003
)
0.93
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010
)
0.36
" Moxonidine is well tolerated; its bioavailability after oral intake reaches 90%."( [Analysis of efficacy and safety of administration of moxonidine in patients with arterial hypertension and hypertensive crises].
Abdrakhmanov, VR; Baratashvili, VL; Gaponova, NI; Tereshchenko, SN, 2011
)
1.53
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Moxonidine is a selective ligand at I1-R, had no influence on the dose-response curve of moxonidine (log EC50: -6.5). The combination of mxonidine and hydrochlorothiazide in the same dosage as a monotherapy improves efficacy without additive effects on the safety profile.

ExcerptRelevanceReference
" Compliance may be aided by the once- or twice-daily administration schedule with moxonidine, and dosage adjustment is only necessary in patients with moderate renal impairment."( Moxonidine. A review of its pharmacology, and therapeutic use in essential hypertension.
Chrisp, P; Faulds, D, 1992
)
1.95
" Cumulative dose-response (i."( Evidence that different regional sympathetic outflows vary in their sensitivity to the sympathoinhibitory actions of putative 5-HT1A and alpha 2-adrenoceptor agonists in anaesthetized cats.
Ramage, AG; Wilkinson, SJ, 1989
)
0.28
" Thus, in patients with renal failure, dosage of moxonidine should be individually titrated according to the desired clinical response, as is recommended for hypertensive patients without renal impairment."( The influence of renal function on clinical pharmacokinetics of moxonidine.
Hutt, HJ; Kirch, W; Plänitz, V, 1988
)
0.77
" No significant differences in pharmacokinetic parameters could be observed following repeated dosing over five days."( Pharmacokinetics of moxonidine after single and repeated daily doses in healthy volunteers.
Jähnchen, E; Plänitz, V; Trenk, D; Wagner, F, 1987
)
0.6
" Dose-response curves for the effects on the plasma noradrenaline concentration (stimulated pithed rabbits) were compared with previously obtained dose-response curves for depression of renal sympathetic nerve activity (conscious rabbits)."( Involvement of peripheral presynaptic inhibition in the reduction of sympathetic tone by moxonidine, rilmenidine and UK 14304.
Starke, K; Szabo, B; Urban, R, 1995
)
0.51
" Dose-response curves were generated for para-aminoclonidine in the presence of vehicle alone, yohimbine (alpha-2 antagonist), idazoxan (alpha-2/I1/I2 antagonist) and prazosin (alpha-1 antagonist)."( Identification, localization and functional analysis of imidazoline and alpha adrenergic receptors in canine prostate.
Breslin, DS; Ernsberger, P; Felsen, D; Marion, DN; May, M; Nejat, RJ; Nguyen, P; Sutaria, PM; Vaughan, ED, 1994
)
0.29
" The combination of moxonidine and hydrochlorothiazide in the same dosage as a monotherapy improves efficacy significantly without additive effects on the safety profile."( Moxonidine and hydrochlorothiazide in combination: a synergistic antihypertensive effect.
Frei, M; Gardosch von Krosigk, PP; Koch, HF; Küppers, H; Küster, L, 1994
)
2.05
"We determined the relative potency of these drugs with respect to their effects on mean arterial pressure and heart rate by performing cumulative intravenous dose-response relationship studies in six conscious rabbits."( Relative importance of central imidazoline receptors for the antihypertensive effects of moxonidine and rilmenidine.
Chan, CK; Head, GA, 1996
)
0.52
" Initial dose-response studies showed that agmatine administered in low doses (0."( Central cardiovascular actions of agmatine, a putative clonidine-displacing substance, in conscious rabbits.
Chan, CK; Godwin, SJ; Head, GA, 1997
)
0.3
" Repeat dosing with moxonidine produced an impairment of memory scanning performance."( Moxonidine and cognitive function: interactions with moclobemide and lorazepam.
Grahnén, A; Jansson, B; Küppers, H; Simpson, PM; Weimann, HJ; Wesnes, K, 1997
)
2.06
" At a practical level, moxonidine is suitable for single daily dosing in hypertension."( Moxonidine: pharmacology, clinical pharmacology and clinical profile.
Elliott, HL, 1998
)
2.05
" Both drugs, when applied in a once-daily dosage schedule, appear to control hypertension in most patients."( Central I1-imidazoline receptors as targets of centrally acting antihypertensive drugs. Clinical pharmacology of moxonidine and rilmenidine.
Peters, SL; Van Zwieten, PA, 1999
)
0.51
" The combinations of moxonidine-morphine and moxonidine-deltorphin II resulted in significant leftward shifts in the dose-response curves compared to those of each agonist administered separately."( Moxonidine, a selective imidazoline/alpha(2) adrenergic receptor agonist, synergizes with morphine and deltorphin II to inhibit substance P-induced behavior in mice.
Fairbanks, CA; Kitto, KF; Posthumus, IJ; Stone, LS; Wilcox, GL, 2000
)
2.07
" Furthermore, the combinations of moxonidine-morphine and clonidine-morphine resulted in substantial leftward shifts in the dose-response curves compared with those of each agonist administered separately."( Moxonidine, a selective imidazoline-alpha2 -adrenergic receptor agonist, produces spinal synergistic antihyperalgesia with morphine in nerve-injured mice.
Fairbanks, CA; Grocholski, BM; Nguyen, HO; Wilcox, GL, 2000
)
2.03
" We investigated the dose-response relationship of a new sustained-release (SR) preparation of moxonidine and the plasma concentration of norepinephrine in patients with chronic heart failure."( Effects of sustained-release moxonidine, an imidazoline agonist, on plasma norepinephrine in patients with chronic heart failure.
Bristow, MR; Cohn, JN; Dargie, H; Straub, M; Swedberg, K; Wiltse, C; Wright, TJ, 2002
)
0.82
"To test the hypothesis that the renal clearance of moxonidine decreases when dosed with quinidine."( Quinidine does not affect the renal clearance of moxonidine.
Chan, C; He, MM; Mitchell, MI; Pouliquen, IJ; Schaefer, HG; Wise, SD, 2002
)
0.82
" AGN192403, a selective ligand at I1-R, had no influence on the dose-response curve of moxonidine (log EC50: -6."( Presynaptic effects of moxonidine in isolated buffer perfused rat hearts: role of imidazoline-1 receptors and alpha2-adrenoceptors.
Burgdorf, C; Engelhardt, A; Kurz, T; Richardt, G; Schäfer, U, 2002
)
0.85
" Similar responses were observed after oral dosing and in lean littermates."( The role of I(1)-imidazoline and alpha(2)-adrenergic receptors in the modulation of glucose metabolism in the spontaneously hypertensive obese rat model of metabolic syndrome X.
Ernsberger, P; Velliquette, RA, 2003
)
0.32
" Dose-response curves were determined for phenylephrine and for several imidazoline ligands, using endothelium denuded, isolated ring segments, of tail arteries from adult male Sprague-Dawley rats."( Centrally acting imidazolines stimulate vascular alpha 1A-adrenergic receptors in Rat-Tail Artery.
Crane, L; Edwards, LP; George, OK; Gonzalez, RR; Kennedy, WB,
)
0.13
" In dose-response experiments, the maximal response (E(max)) was markedly reduced 18."( Marked insulin resistance in obese spontaneously hypertensive rat adipocytes is ameliorated by in vivo but not in vitro treatment with moxonidine.
Ernsberger, P; Sun, Z, 2007
)
0.54
" Along with the metabolic neutrality for the lipid and purine metabolism, the drug demonstrated a distinct antihypertensive effect, which against the background of pronounced sympatholytic action after 3 months of therapy tends to disappear, which can be prevented by dosage correction."( Pecularities of prolonged use of moxonidine in patients with hypertension associated with metabolic syndrome.
Borodulina, EV; Gridneva, TD; Kseneva, SI; Kulakova, NV; Semiglazova, TA; Tarasova, IV; Trifonova, OJ; Udut, VV, 2011
)
0.65
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
organohalogen compoundA compound containing at least one carbon-halogen bond (where X is a halogen atom).
pyrimidinesAny compound having a pyrimidine as part of its structure.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (24)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
GALC proteinHomo sapiens (human)Potency0.707928.183828.183828.1838AID1159614
GLS proteinHomo sapiens (human)Potency31.62280.35487.935539.8107AID624146
EWS/FLI fusion proteinHomo sapiens (human)Potency0.01320.001310.157742.8575AID1259253
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency12.58930.035520.977089.1251AID504332
heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa)Homo sapiens (human)Potency58.47890.016525.307841.3999AID602332
aryl hydrocarbon receptorHomo sapiens (human)Potency9.21880.000723.06741,258.9301AID743085; AID743122
cytochrome P450 2C19 precursorHomo sapiens (human)Potency39.81070.00255.840031.6228AID899
gemininHomo sapiens (human)Potency28.18380.004611.374133.4983AID624297
muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Potency17.78280.00106.000935.4813AID944
lamin isoform A-delta10Homo sapiens (human)Potency0.39810.891312.067628.1838AID1487
Rap guanine nucleotide exchange factor 4Homo sapiens (human)Potency100.00003.981146.7448112.2020AID720708
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Alpha-2A adrenergic receptorHomo sapiens (human)Ki0.11250.00010.807410.0000AID1195979; AID35934
Alpha-2B adrenergic receptorHomo sapiens (human)Ki0.07500.00020.725710.0000AID1195979
Alpha-2C adrenergic receptorHomo sapiens (human)Ki1.03750.00030.483410.0000AID1195979; AID36396
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)IC50 (µMol)0.70210.00031.38338.4000AID625190
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)Ki0.40120.00010.739610.0000AID625190
Alpha-2B adrenergic receptorRattus norvegicus (Norway rat)Ki1.00000.00000.929610.0000AID36251
Alpha-1D adrenergic receptorHomo sapiens (human)Ki15.50000.00000.360910.0000AID36128; AID36251
5-hydroxytryptamine receptor 1BRattus norvegicus (Norway rat)IC50 (µMol)0.70210.00051.48357.8000AID625190
5-hydroxytryptamine receptor 1BRattus norvegicus (Norway rat)Ki0.40120.00031.29679.2440AID625190
Delta-type opioid receptorMus musculus (house mouse)Ki0.07780.00000.53939.4000AID1195978
Alpha-1A adrenergic receptorHomo sapiens (human)Ki15.50000.00000.272610.0000AID36128; AID36251
Alpha-1B adrenergic receptorHomo sapiens (human)Ki15.50000.00000.471310.0000AID36128; AID36251
Mu-type opioid receptorCavia porcellus (domestic guinea pig)Ki0.07780.00000.27869.0000AID1195978
NischarinRattus norvegicus (Norway rat)Ki0.07780.00080.13881.2589AID1195978
NischarinHomo sapiens (human)Ki0.03010.00420.21923.8019AID223225; AID342861
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (90)

Processvia Protein(s)Taxonomy
positive regulation of cytokine productionAlpha-2A adrenergic receptorHomo sapiens (human)
DNA replicationAlpha-2A adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
Ras protein signal transductionAlpha-2A adrenergic receptorHomo sapiens (human)
Rho protein signal transductionAlpha-2A adrenergic receptorHomo sapiens (human)
female pregnancyAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of cell population proliferationAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2A adrenergic receptorHomo sapiens (human)
regulation of vasoconstrictionAlpha-2A adrenergic receptorHomo sapiens (human)
actin cytoskeleton organizationAlpha-2A adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of cell migrationAlpha-2A adrenergic receptorHomo sapiens (human)
activation of protein kinase activityAlpha-2A adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2A adrenergic receptorHomo sapiens (human)
cellular response to hormone stimulusAlpha-2A adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2A adrenergic receptorHomo sapiens (human)
vasodilationAlpha-2A adrenergic receptorHomo sapiens (human)
glucose homeostasisAlpha-2A adrenergic receptorHomo sapiens (human)
fear responseAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of potassium ion transportAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of MAP kinase activityAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion-dependent exocytosisAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretionAlpha-2A adrenergic receptorHomo sapiens (human)
intestinal absorptionAlpha-2A adrenergic receptorHomo sapiens (human)
thermoceptionAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of lipid catabolic processAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of membrane protein ectodomain proteolysisAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion transportAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretion involved in cellular response to glucose stimulusAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of uterine smooth muscle contractionAlpha-2A adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-inhibiting adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
phospholipase C-activating adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of wound healingAlpha-2A adrenergic receptorHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion transmembrane transporter activityAlpha-2A adrenergic receptorHomo sapiens (human)
MAPK cascadeAlpha-2B adrenergic receptorHomo sapiens (human)
angiogenesisAlpha-2B adrenergic receptorHomo sapiens (human)
regulation of vascular associated smooth muscle contractionAlpha-2B adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-2B adrenergic receptorHomo sapiens (human)
female pregnancyAlpha-2B adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2B adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2B adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2B adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2B adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of neuron differentiationAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of blood pressureAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of uterine smooth muscle contractionAlpha-2B adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
regulation of smooth muscle contractionAlpha-2C adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2C adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-2C adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2C adrenergic receptorHomo sapiens (human)
regulation of vasoconstrictionAlpha-2C adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2C adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2C adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2C adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2C adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2C adrenergic receptorHomo sapiens (human)
positive regulation of neuron differentiationAlpha-2C adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2C adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2C adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretionAlpha-2C adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of cell population proliferationAlpha-1D adrenergic receptorHomo sapiens (human)
neuron-glial cell signalingAlpha-1D adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-1D adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of vasoconstrictionAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-1D adrenergic receptorHomo sapiens (human)
MAPK cascadeAlpha-1A adrenergic receptorHomo sapiens (human)
negative regulation of heart rate involved in baroreceptor response to increased systemic arterial blood pressureAlpha-1A adrenergic receptorHomo sapiens (human)
norepinephrine-epinephrine vasoconstriction involved in regulation of systemic arterial blood pressureAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of heart rate by epinephrine-norepinephrineAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of the force of heart contraction by epinephrine-norepinephrineAlpha-1A adrenergic receptorHomo sapiens (human)
apoptotic processAlpha-1A adrenergic receptorHomo sapiens (human)
smooth muscle contractionAlpha-1A adrenergic receptorHomo sapiens (human)
signal transductionAlpha-1A adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-1A adrenergic receptorHomo sapiens (human)
activation of phospholipase C activityAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationAlpha-1A adrenergic receptorHomo sapiens (human)
adult heart developmentAlpha-1A adrenergic receptorHomo sapiens (human)
negative regulation of cell population proliferationAlpha-1A adrenergic receptorHomo sapiens (human)
response to xenobiotic stimulusAlpha-1A adrenergic receptorHomo sapiens (human)
response to hormoneAlpha-1A adrenergic receptorHomo sapiens (human)
negative regulation of autophagyAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of cardiac muscle hypertrophyAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of synaptic transmission, GABAergicAlpha-1A adrenergic receptorHomo sapiens (human)
intracellular signal transductionAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of action potentialAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of vasoconstrictionAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of smooth muscle contractionAlpha-1A adrenergic receptorHomo sapiens (human)
calcium ion transport into cytosolAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of cardiac muscle contractionAlpha-1A adrenergic receptorHomo sapiens (human)
cell growth involved in cardiac muscle cell developmentAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of protein kinase C signalingAlpha-1A adrenergic receptorHomo sapiens (human)
pilomotor reflexAlpha-1A adrenergic receptorHomo sapiens (human)
neuron-glial cell signalingAlpha-1A adrenergic receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayAlpha-1A adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-1A adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-1A adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-1B adrenergic receptorHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayAlpha-1B adrenergic receptorHomo sapiens (human)
regulation of vasoconstrictionAlpha-1B adrenergic receptorHomo sapiens (human)
intracellular signal transductionAlpha-1B adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-1B adrenergic receptorHomo sapiens (human)
regulation of cardiac muscle contractionAlpha-1B adrenergic receptorHomo sapiens (human)
neuron-glial cell signalingAlpha-1B adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-1B adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-1B adrenergic receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayAlpha-1B adrenergic receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationAlpha-1B adrenergic receptorHomo sapiens (human)
adaptive immune responseRap guanine nucleotide exchange factor 4Homo sapiens (human)
G protein-coupled receptor signaling pathwayRap guanine nucleotide exchange factor 4Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayRap guanine nucleotide exchange factor 4Homo sapiens (human)
calcium-ion regulated exocytosisRap guanine nucleotide exchange factor 4Homo sapiens (human)
regulation of exocytosisRap guanine nucleotide exchange factor 4Homo sapiens (human)
insulin secretionRap guanine nucleotide exchange factor 4Homo sapiens (human)
positive regulation of insulin secretionRap guanine nucleotide exchange factor 4Homo sapiens (human)
regulation of synaptic vesicle cycleRap guanine nucleotide exchange factor 4Homo sapiens (human)
Ras protein signal transductionRap guanine nucleotide exchange factor 4Homo sapiens (human)
regulation of insulin secretionRap guanine nucleotide exchange factor 4Homo sapiens (human)
apoptotic processNischarinHomo sapiens (human)
Rac protein signal transductionNischarinHomo sapiens (human)
actin cytoskeleton organizationNischarinHomo sapiens (human)
negative regulation of cell migrationNischarinHomo sapiens (human)
outer dynein arm assemblyNischarinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (22)

Processvia Protein(s)Taxonomy
alpha2-adrenergic receptor activityAlpha-2A adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2A adrenergic receptorHomo sapiens (human)
protein kinase bindingAlpha-2A adrenergic receptorHomo sapiens (human)
alpha-1B adrenergic receptor bindingAlpha-2A adrenergic receptorHomo sapiens (human)
alpha-2C adrenergic receptor bindingAlpha-2A adrenergic receptorHomo sapiens (human)
thioesterase bindingAlpha-2A adrenergic receptorHomo sapiens (human)
heterotrimeric G-protein bindingAlpha-2A adrenergic receptorHomo sapiens (human)
protein homodimerization activityAlpha-2A adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-2A adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2A adrenergic receptorHomo sapiens (human)
norepinephrine bindingAlpha-2A adrenergic receptorHomo sapiens (human)
guanyl-nucleotide exchange factor activityAlpha-2A adrenergic receptorHomo sapiens (human)
alpha2-adrenergic receptor activityAlpha-2B adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2B adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2B adrenergic receptorHomo sapiens (human)
alpha2-adrenergic receptor activityAlpha-2C adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2C adrenergic receptorHomo sapiens (human)
alpha-2A adrenergic receptor bindingAlpha-2C adrenergic receptorHomo sapiens (human)
protein homodimerization activityAlpha-2C adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-2C adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2C adrenergic receptorHomo sapiens (human)
guanyl-nucleotide exchange factor activityAlpha-2C adrenergic receptorHomo sapiens (human)
protein bindingAlpha-1D adrenergic receptorHomo sapiens (human)
identical protein bindingAlpha-1D adrenergic receptorHomo sapiens (human)
alpha1-adrenergic receptor activityAlpha-1D adrenergic receptorHomo sapiens (human)
alpha1-adrenergic receptor activityAlpha-1A adrenergic receptorHomo sapiens (human)
protein bindingAlpha-1A adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-1A adrenergic receptorHomo sapiens (human)
protein bindingAlpha-1B adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-1B adrenergic receptorHomo sapiens (human)
alpha1-adrenergic receptor activityAlpha-1B adrenergic receptorHomo sapiens (human)
guanyl-nucleotide exchange factor activityRap guanine nucleotide exchange factor 4Homo sapiens (human)
protein bindingRap guanine nucleotide exchange factor 4Homo sapiens (human)
cAMP bindingRap guanine nucleotide exchange factor 4Homo sapiens (human)
protein-macromolecule adaptor activityRap guanine nucleotide exchange factor 4Homo sapiens (human)
small GTPase bindingRap guanine nucleotide exchange factor 4Homo sapiens (human)
integrin bindingNischarinHomo sapiens (human)
protein bindingNischarinHomo sapiens (human)
phosphatidylinositol bindingNischarinHomo sapiens (human)
identical protein bindingNischarinHomo sapiens (human)
dynein heavy chain bindingNischarinHomo sapiens (human)
alpha-tubulin bindingNischarinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (25)

Processvia Protein(s)Taxonomy
cytoplasmAlpha-2A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
basolateral plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
neuronal cell bodyAlpha-2A adrenergic receptorHomo sapiens (human)
axon terminusAlpha-2A adrenergic receptorHomo sapiens (human)
presynaptic active zone membraneAlpha-2A adrenergic receptorHomo sapiens (human)
dopaminergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
postsynaptic density membraneAlpha-2A adrenergic receptorHomo sapiens (human)
glutamatergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
GABA-ergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
receptor complexAlpha-2A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
cytosolAlpha-2B adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2B adrenergic receptorHomo sapiens (human)
cell surfaceAlpha-2B adrenergic receptorHomo sapiens (human)
intracellular membrane-bounded organelleAlpha-2B adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2B adrenergic receptorHomo sapiens (human)
cytoplasmAlpha-2C adrenergic receptorHomo sapiens (human)
endosomeAlpha-2C adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2C adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2C adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-1D adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-1D adrenergic receptorHomo sapiens (human)
nucleusAlpha-1A adrenergic receptorHomo sapiens (human)
nucleoplasmAlpha-1A adrenergic receptorHomo sapiens (human)
cytoplasmAlpha-1A adrenergic receptorHomo sapiens (human)
cytosolAlpha-1A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-1A adrenergic receptorHomo sapiens (human)
caveolaAlpha-1A adrenergic receptorHomo sapiens (human)
nuclear membraneAlpha-1A adrenergic receptorHomo sapiens (human)
intracellular membrane-bounded organelleAlpha-1A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-1A adrenergic receptorHomo sapiens (human)
nucleusAlpha-1B adrenergic receptorHomo sapiens (human)
cytoplasmAlpha-1B adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-1B adrenergic receptorHomo sapiens (human)
caveolaAlpha-1B adrenergic receptorHomo sapiens (human)
nuclear membraneAlpha-1B adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-1B adrenergic receptorHomo sapiens (human)
cytosolRap guanine nucleotide exchange factor 4Homo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 4Homo sapiens (human)
membraneRap guanine nucleotide exchange factor 4Homo sapiens (human)
hippocampal mossy fiber to CA3 synapseRap guanine nucleotide exchange factor 4Homo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 4Homo sapiens (human)
nucleoplasmNischarinHomo sapiens (human)
early endosomeNischarinHomo sapiens (human)
cytosolNischarinHomo sapiens (human)
plasma membraneNischarinHomo sapiens (human)
microtubule cytoskeletonNischarinHomo sapiens (human)
membraneNischarinHomo sapiens (human)
intracellular membrane-bounded organelleNischarinHomo sapiens (human)
intercellular bridgeNischarinHomo sapiens (human)
recycling endosomeNischarinHomo sapiens (human)
cytoplasmNischarinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (112)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1195978Displacement of [125I] PIC from I1 imidazoline receptor in rat PC12 cells after 45 mins by gamma counting2015Journal of medicinal chemistry, Jan-22, Volume: 58, Issue:2
Synthesis and biological evaluation of 2-aryliminopyrrolidines as selective ligands for I1 imidazoline receptors: discovery of new sympatho-inhibitory hypotensive agents with potential beneficial effects in metabolic syndrome.
AID36396Binding affinity for human Alpha-2C adrenergic receptor1996Journal of medicinal chemistry, Mar-15, Volume: 39, Issue:6
Synthesis and pharmacologic evaluation of 2-endo-amino-3-exo-isopropylbicyclo[2.2.1]heptane: a potent imidazoline1 receptor specific agent.
AID476929Human intestinal absorption in po dosed human2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
AID444057Fraction escaping hepatic elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID503832Partial agonist activity at adrenergic alpha2A receptor expressed in HEK293 cells coexpressing yellow fluorescent and cyan fluorescent protein assessed as effect on kinetics of receptor conformational change by FRET assay2005Nature chemical biology, Jun, Volume: 1, Issue:1
Molecular basis of inverse agonism in a G protein-coupled receptor.
AID1195980Selectivity ratio of Ki for I1 imidazoline receptor in rat PC12 cells to Ki for human alpha2 adrenoceptor expressed in CHO cell membranes2015Journal of medicinal chemistry, Jan-22, Volume: 58, Issue:2
Synthesis and biological evaluation of 2-aryliminopyrrolidines as selective ligands for I1 imidazoline receptors: discovery of new sympatho-inhibitory hypotensive agents with potential beneficial effects in metabolic syndrome.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID444050Fraction unbound in human plasma2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1306489Induction of apoptosis in human K562 cells assessed as early apoptotic cells at 300 uM after 48 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 5%)2016Bioorganic & medicinal chemistry, 07-15, Volume: 24, Issue:14
A combined ligand- and structure-based approach for the identification of rilmenidine-derived compounds which synergize the antitumor effects of doxorubicin.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID444058Volume of distribution at steady state in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID444052Hepatic clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID444055Fraction absorbed in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID444051Total clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID36251Binding affinity for rat Alpha-2B adrenergic receptor1996Journal of medicinal chemistry, Mar-15, Volume: 39, Issue:6
Synthesis and pharmacologic evaluation of 2-endo-amino-3-exo-isopropylbicyclo[2.2.1]heptane: a potent imidazoline1 receptor specific agent.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID35772Compound was evaluated for hypotensive activity mediated by Alpha-2 adrenergic receptor; no data2003Journal of medicinal chemistry, May-08, Volume: 46, Issue:10
Synthesis and biological evaluation of new 2-(4,5-dihydro-1H-imidazol-2-yl)-3,4-dihydro-2H-1,4-benzoxazine derivatives.
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID1767741Displacement of [3H]clonidine from imidazoline I1 receptor low affinity site in human hypothalamic membranes measured after 30 mins by liquid scintillation counting spectrometry2021European journal of medicinal chemistry, Oct-15, Volume: 222Benzofuranyl-2-imidazoles as imidazoline I
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1195979Displacement of [3H]RX821002 from human alpha2 adrenoceptor expressed in CHO cell membranes after 60 mins2015Journal of medicinal chemistry, Jan-22, Volume: 58, Issue:2
Synthesis and biological evaluation of 2-aryliminopyrrolidines as selective ligands for I1 imidazoline receptors: discovery of new sympatho-inhibitory hypotensive agents with potential beneficial effects in metabolic syndrome.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1561260Displacement of [3H]clonidine from I1IR in human brain frontal cortex in presence of adrenaline incubated for 45 mins by liquid scintillation spectrometry2020Journal of medicinal chemistry, 04-09, Volume: 63, Issue:7
Bicyclic α-Iminophosphonates as High Affinity Imidazoline I
AID1317097Selectivity ratio of agonist activity at I1 receptor imidazoline binding site (unknown origin) to agonist activity at alpha2-AR (unknown origin)
AID1767742Displacement of [3H]clonidine from imidazoline I1 receptor high affinity site in human hypothalamic membranes measured after 30 mins by liquid scintillation counting spectrometry2021European journal of medicinal chemistry, Oct-15, Volume: 222Benzofuranyl-2-imidazoles as imidazoline I
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID35934Binding affinity for human Alpha-2A adrenergic receptor1996Journal of medicinal chemistry, Mar-15, Volume: 39, Issue:6
Synthesis and pharmacologic evaluation of 2-endo-amino-3-exo-isopropylbicyclo[2.2.1]heptane: a potent imidazoline1 receptor specific agent.
AID223225Displacement of [3H]-clonidine from bovine imidazoline receptor I-11996Journal of medicinal chemistry, Mar-15, Volume: 39, Issue:6
Synthesis and pharmacologic evaluation of 2-endo-amino-3-exo-isopropylbicyclo[2.2.1]heptane: a potent imidazoline1 receptor specific agent.
AID1306488Induction of apoptosis in human K562 cells assessed as early apoptotic cells at 300 uM after 24 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 5%)2016Bioorganic & medicinal chemistry, 07-15, Volume: 24, Issue:14
A combined ligand- and structure-based approach for the identification of rilmenidine-derived compounds which synergize the antitumor effects of doxorubicin.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID444056Fraction escaping gut-wall elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID342861Displacement of [125I]PIC from human imidazoline receptor 1 in human platelets analyzed under norepinephrine mask of alpha 2AR2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
QSAR study of imidazoline antihypertensive drugs.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID567091Drug absorption in human assessed as human intestinal absorption rate2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID444053Renal clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID444054Oral bioavailability in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID36128Binding affinity for human brain Alpha-1 adrenergic receptor1996Journal of medicinal chemistry, Mar-15, Volume: 39, Issue:6
Synthesis and pharmacologic evaluation of 2-endo-amino-3-exo-isopropylbicyclo[2.2.1]heptane: a potent imidazoline1 receptor specific agent.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (472)

TimeframeStudies, This Drug (%)All Drugs %
pre-19909 (1.91)18.7374
1990's168 (35.59)18.2507
2000's189 (40.04)29.6817
2010's91 (19.28)24.3611
2020's15 (3.18)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 75.88

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index75.88 (24.57)
Research Supply Index6.38 (2.92)
Research Growth Index5.98 (4.65)
Search Engine Demand Index130.64 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (75.88)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials86 (17.03%)5.53%
Reviews66 (13.07%)6.00%
Case Studies8 (1.58%)4.05%
Observational0 (0.00%)0.25%
Other345 (68.32%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (20)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Randomised Trial Examining the Effectiveness of Sympathetic Nervous Inhibition in Alleviating the Metabolic Side Effects of Antipsychotic Medications in Patients With Schizophrenia [NCT01567124]Phase 40 participants (Actual)Interventional2012-05-31Withdrawn
The Effect of Moxonidine and Regression of Early Target Organ Damage in Young Subjects With Abdominal Obesity and Hypertension: a Randomised, Double Blind, Active Comparator Clinical Trial [NCT01360710]Phase 4100 participants (Anticipated)Interventional2012-01-31Recruiting
A Randomized, Placebo-controlled, Double Blind, 4-period, Cross-over Trial, to Study the Effects of Aliskiren, Hydrochlorothiazide and Moxonidine on Endothelial Dysfunction in Obesity Related Hypertension [NCT01138423]Phase 432 participants (Actual)Interventional2010-08-31Completed
Assessment of the Effect of Moxonidine and Diet on Cardiac, Renal and Endothelial Function in Young Subjects With Abdominal Obesity [NCT01180231]Phase 477 participants (Anticipated)Interventional2010-09-30Recruiting
Autonomic Determinants of Postural Tachycardia Syndrome (Chronic Pilot Study 2) [NCT04140721]Early Phase 148 participants (Anticipated)Interventional2021-08-31Recruiting
Sympathetic Mechanisms in the Cardiovascular and Metabolic Alterations of Obesity [NCT04329806]Phase 172 participants (Anticipated)Interventional2021-02-23Suspended(stopped due to Study being replaced by crossover design)
Open Label, Multi-Center, Force-Titration Study to Evaluate the Efficacy and Safety of Moxonidine in Ambulatory Subjects With Essential Hypertension [NCT00160277]Phase 3100 participants Interventional2005-07-31Completed
Effects of Moxonidine Administration on Serum Neuropeptide Y Levels in Hypertensive Individuals: A Prospective Observational Study [NCT05147753]Phase 490 participants (Actual)Interventional2010-01-11Completed
The Effects of Small Doses of Moxonidine in Patients Undergoing Vascular Surgery [NCT00244504]Phase 3141 participants (Actual)Interventional2002-11-30Terminated(stopped due to Study was stopped after pre-definied interim analysis because of no effects)
Intensive Non-Sympathetic Activating Vasodilatory Treatment in Hypertensive Patients With Microvascular Angina Pectoris [NCT00424801]10 participants (Actual)Interventional2007-01-31Terminated(stopped due to Due to recent findings relating MRI contrast to nephrogenic systemic fibrosis)
Pathophysiological Mechanisms of Hypertensive LVH:Optimising Regression [NCT00518479]42 participants (Actual)Interventional2003-09-30Completed
Sympathetic Mechanisms in the Cardiovascular and Metabolic Alterations of Obesity, Crossover Design Study. [NCT05312892]Phase 1/Phase 212 participants (Anticipated)Interventional2022-05-20Recruiting
Polycystic Ovary Syndrome - Targeting the Sympathetic Nervous System to Improve Outcomes [NCT01504321]Phase 442 participants (Actual)Interventional2012-05-31Completed
Comparative Effects of Moxonidine and Bisoprolol on Bone Metabolism, Vascular and Cellular Markers of Aging, Blood Pressure in Hypertensive Postmenopausal Women (COMPASS) [NCT02355821]114 participants (Actual)Interventional2015-04-30Completed
Sympathoinhibition as a Preferred Second Line Treatment of Obesity Related Hypertension [NCT04474899]Phase 4120 participants (Anticipated)Interventional2015-06-24Recruiting
Role of Sympathetic Activation in Ischemia Reperfusion Injury [NCT04479813]Phase 446 participants (Actual)Interventional2015-07-08Completed
Open-Label Non-Comparative Study of the Effects of a Combination Antihypertensive Treatment With Moxonidine + Perindopril in Hypertensive Patients With Metabolic Syndrome [NCT04023565]Phase 4120 participants (Anticipated)Interventional2019-03-11Recruiting
Autonomic Determinants of Postural Tachycardia Syndrome (Acute Pilot Study 1) [NCT04050410]Early Phase 148 participants (Anticipated)Interventional2019-08-27Recruiting
Pharmacologic Suppression of Central Sympathetic Activity for Prevention of Atrial Fibrillation Recurrence After Pulmonary Vein Isolation (MOXAF) [NCT01791699]Phase 4150 participants (Anticipated)Interventional2012-08-31Completed
Sympathetic Nervous System Inhibition for the Treatment of Diabetic Nephropathy [NCT01094769]Phase 448 participants (Anticipated)Interventional2011-04-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT02355821 (9) [back to overview]Number of Participants With Adverse Events (AE)
NCT02355821 (9) [back to overview]THe Number (Percentage) of the Treatment Responders
NCT02355821 (9) [back to overview]Bone Mineral Density (BMD) Using Control Dual-energy X-ray Absorptiometry
NCT02355821 (9) [back to overview]Collagen Type 1 C-telopeptide
NCT02355821 (9) [back to overview]Intima-media Thickness (IMT)
NCT02355821 (9) [back to overview]Osteocalcin
NCT02355821 (9) [back to overview]Pulse Wave Velocity (PWV)
NCT02355821 (9) [back to overview]Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL).
NCT02355821 (9) [back to overview]Telomerase Activity

Number of Participants With Adverse Events (AE)

Number of Participants with Adverse Events (AE) (NCT02355821)
Timeframe: baseline (Visit 1) and 12 months (Visit 4)

InterventionParticipants (Count of Participants)
Moxonidine3
Bisoprolol3

[back to top]

THe Number (Percentage) of the Treatment Responders

Proportion of the treatment responders (defined as the proportion (%) of patients who achieved target blood pressure <140/90 mmHg) after 8 and 48 weeks of the investigated treatment (V2, V3 and V4) and to compare the values between the groups. (NCT02355821)
Timeframe: baseline (Visit 1) and 12 months (Visit 4)

InterventionParticipants (Count of Participants)
Moxonidine55
Bisoprolol53

[back to top]

Bone Mineral Density (BMD) Using Control Dual-energy X-ray Absorptiometry

Changes in Median (Inter-Quartile Range) values of Bone mineral density (BMD) at final visit versus baseline level using control dual-energy X-ray absorptiometry and in comparison between the groups (NCT02355821)
Timeframe: 12 months

,
Interventiong/cm2 (Median)
Baseline12 months
Bisoprolol-0.55-1.2
Moxonidine-1.0-0.6

[back to top]

Collagen Type 1 C-telopeptide

Changes in Median (Inter-Quartile Range) of the bone resorption marker (collagen type 1 C-telopeptide) at the end of the study from the baseline are evaluated in comparison between the groups (NCT02355821)
Timeframe: baseline (Visit 1) and 12 months (Visit 4)

,
Interventionng/ml (Median)
Baseline12 months
Bisoprolol0.40.4
Moxonidine0.40.3

[back to top]

Intima-media Thickness (IMT)

Changes in mean intima-media thickness (IMT) at final visit in comparison between the groups. (NCT02355821)
Timeframe: baseline (Visit 1) and 12 months (Visit 4)

,
Interventionmm (Mean)
Baseline12 months
Bisoprolol0.980.88
Moxonidine0.980.77

[back to top]

Osteocalcin

Changes in Median (Inter-Quartile Range) values of the bone synthesis marker (osteocalcin) at the end of the study (V4) from the baseline (V1) and to compare the values between the groups. (NCT02355821)
Timeframe: baseline (Visit 1) and 12 months (Visit 4)

,
Interventionng/ml (Median)
Baseline12 months
Bisoprolol19.418.7
Moxonidine18.219.6

[back to top]

Pulse Wave Velocity (PWV)

Changes in mean pulse wave velocity (PWV) at final visit versus baseline level and in comparison between the groups (NCT02355821)
Timeframe: baseline (Visit 1) and 12 months (Visit 4)

,
Interventionm/s (Mean)
Baseline12 months
Bisoprolol10.3611.26
Moxonidine10.3510.05

[back to top]

Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL).

Changes in Median (Inter-Quartile Range) values of the receptor activator of nuclear factor kappa-B ligand (RANKL) at final visit versus baseline level in comparison between the groups (NCT02355821)
Timeframe: baseline (Visit 1) and 12 months (Visit 4)

,
Interventionpmol/ml (Median)
Baseline12 month
Bisoprolol0.1330.111
Moxonidine0.1090.09

[back to top]

Telomerase Activity

Changes in Median (Inter-Quartile Range) telomerase activity at final visit versus baseline level in comparison between the groups Telomerase activity is measured in arbitrary units. Currently, there are no established reference values for telomerase activity in the world. Its activity is considered high or low in relation to the median. (NCT02355821)
Timeframe: baseline (Visit 1) and 12 months (Visit 4)

,
Interventionarbitrary units (Median)
Baseline12 months
Bisoprolol0.890.64
Moxonidine0.871.15

[back to top]